Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis

Hruby, 2015, The epidemiology of obesity: a big picture, Pharmacoeconomics, 33, 673, 10.1007/s40273-014-0243-x Feng, 2016, Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies, Medicine (Baltimore), 95, e2859, 10.1097/MD.0000000000002859 Qin, 2015, Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis, Arthritis Res Ther, 17, 86, 10.1186/s13075-015-0601-x Harpsøe, 2014, Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort, Int J Epidemiol, 43, 843, 10.1093/ije/dyu045 Hou, 2011, Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature, Am J Gastroenterol, 106, 563, 10.1038/ajg.2011.44 Munger, 2009, Body size and risk of MS in two cohorts of US women, Neurology, 73, 1543, 10.1212/WNL.0b013e3181c0d6e0 Hedström, 2012, High body index before age 20 is associated with increased risk for multiple sclerosis men and women, Mult Scler J, 18, 1334, 10.1177/1352458512436596 Maas, 2016, Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome, J Rheumatol, 43, 383, 10.3899/jrheum.150648 Armstrong, 2012, The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies, Nutr Diabetes, 2, e54, 10.1038/nutd.2012.26 Love, 2012, Obesity and the risk of psoriatic arthritis: a population-based study, Ann Rheum Dis, 71, 1273, 10.1136/annrheumdis-2012-201299 Li, 2012, Obesity and risk of incident psoriatic arthritis in US women, Ann Rheum Dis, 71, 1267, 10.1136/annrheumdis-2011-201273 de Heredia, 2012, Obesity, inflammation and the immune system, Proc Nutr Soc, 71, 332, 10.1017/S0029665112000092 Versini, 2014, Obesity in autoimmune diseases: not a passive bystander, Autoimmun Rev, 13, 981, 10.1016/j.autrev.2014.07.001 Vidal, 2015, Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and meta-analysis, J Rheumatol, 42, 2261, 10.3899/jrheum.150224 Liu, 2017, Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis, Arthritis Care Res (Hoboken), 69, 157, 10.1002/acr.22932 Klaasen, 2011, Body mass index and clinical response to infliximab in rheumatoid arthritis, Arthritis Rheum, 63, 359, 10.1002/art.30136 Gremese, 2013, Obesity and reduction of the response rate to anti–tumor necrosis factor in rheumatoid arthritis: an approach to a personalized medicine, Arthritis Care Res (Hoboken), 65, 94, 10.1002/acr.21768 Iannone, 2015, Obesity reduces the drug survival of second line biological drugs following a first TNF- inhibitor in rheumatoid arthritis patients, Joint Bone Spine, 82, 187, 10.1016/j.jbspin.2014.12.006 Kim, 2016, No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study, Clin Rheumatol, 35, 1129, 10.1007/s10067-016-3220-2 Gardette, 2016, Body mass index and response to abatacept in rheumatoid arthritis, Eur J Clin Invest, 46, 1048, 10.1111/eci.12691 Iannone, 2017, Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the pan-European registry collaboration for abatacept (PANABA), Clin Rheumatol, 36, 773, 10.1007/s10067-016-3505-5 Mariette, 2017, The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study, Joint Bone Spine, 84, 571, 10.1016/j.jbspin.2016.10.011 D’Agostino, 2017, Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis, Clin Rheumatol, 36, 2655, 10.1007/s10067-017-3788-1 Pers, 2015, Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient, J Rheumatol, 42, 580, 10.3899/jrheum.140673 Gardette, 2016, Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study, Clin Rheumatol, 35, 857, 10.1007/s10067-016-3183-3 Ottaviani, 2012, Body mass index influences the response to infliximab in ankylosing spondylitis, Arthritis Res Ther, 14, R115, 10.1186/ar3841 Rosas, 2017, Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis, Clin Exp Rheumatol, 35, 145 Gremese, 2014, Body weight, gender and response to TNF-a blockers in axial spondyloarthritis, Rheumatology (Oxford), 53, 875, 10.1093/rheumatology/ket433 Micheroli, 2017, Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis, Arthritis Res Ther, 19, 164, 10.1186/s13075-017-1372-3 Harper, 2013, Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease, Dis, 19, 2118 Bhalme, 2013, Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?, Eur J Gastroenterol Hepatol, 25, 543, 10.1097/MEG.0b013e32835d1f15 Brown, 2016, Relationship of body mass index on clinical outcomes after infliximab therapy in patients with Crohn's disease, J Crohns Colitis, 10, 1144, 10.1093/ecco-jcc/jjw079 Guerbau, 2017, Patients with Crohn's disease with high body mass index present more frequent and rapid loss of response to infliximab, Inflamm Bowel Dis, 23, 1853, 10.1097/MIB.0000000000001179 Prussick, 2015, Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis, J Drugs Dermatol, 14, 864 Giunta, 2016, Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: a retrospective study, J Int Med Res, 44, 72, 10.1177/0300060515593254 Iannone, 2013, Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy, Scand J Rheumatol, 42, 41, 10.3109/03009742.2012.715186 Bardazzi, 2010, Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy, Dermatol Ther, 23, S14, 10.1111/j.1529-8019.2009.01281.x Lafuente-Urrez, 2014, Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice, Eur J Dermatol, 24, 217, 10.1684/ejd.2014.2278 Højgaard, 2016, The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries, Rheumatology (Oxford), 55, 2191, 10.1093/rheumatology/kew326 Di Minno, 2014, Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers, Ann Rheum Dis, 73, 1157, 10.1136/annrheumdis-2012-202812 Al-Mutairi, 2014, The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial, Expert Opin Biol Ther, 14, 749, 10.1517/14712598.2014.900541 Ottaviani, 2015, Body mass index and response to rituximab in rheumatoid arthritis, Joint Bone Spine, 82, 432, 10.1016/j.jbspin.2015.02.011 Corbo, 2009, Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity, Ann Rheum Dis, 68, S574 Hanley, 2010, Effect of obesity on the pharmacokinetics of drugs in humans, Clin Pharmacokinet, 49, 71, 10.2165/11318100-000000000-00000 Alzabin, 2012, Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway, Ann Rheum Dis, 71, 1741, 10.1136/annrheumdis-2011-201024 Jhun, 2012, Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation, Exp Mol Med, 44, 424, 10.3858/emm.2012.44.7.047